PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Edmond Yunis to Speak at Antibody Conference June 7-8 in San Diego, California - Edmond Yunis, Professor of Pathology at Harvard Medical School and Chief of Immunogenetics at the Dana-Farber Cancer Institute will give a featured presentation at GTC’s Antibody Design and Discovery Conference (June 7-8, 2012 in San Diego, CA)
Edmond Yunis to Speak at Antibody Conference June 7-8 in San Diego, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/04/24 - Edmond Yunis, Professor of Pathology at Harvard Medical School and Chief of Immunogenetics at the Dana-Farber Cancer Institute will give a featured presentation at GTC’s Antibody Design and Discovery Conference (June 7-8, 2012 in San Diego, CA).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Edmond Yunis, Professor of Pathology at Harvard Medical School and Chief of Immunogenetics at the Dana-Farber Cancer Institute will give a featured presentation on “Humoral Mechanisms and Molecular Signatures of Latent Tuberculosis Infection” at GTC’s Antibody Design and Discovery Conference (June 7-8, 2012 in San Diego, CA)

Innate and adaptive cell-mediated immunity (CMI) play a pivotal role in the response to Mycobacterium tuberculosis (Mtb) infection in experimental models and humans. Humoral immunity is involved in the protection and control of Mtb infection by specific antibodies (neutralizing toxins, promote opsonization and modulation of complement-mediated lysis). High titers of IgG anti-tuberculin antibodies and up-regulation of IL-17 mRNA are signatures of high risk LTBI. Future functional studies need to focus in the mechanisms involved in the early control of Mtb infection and the interplay with host innate and acquired immunity with microbiota to understand the pathogenesis of TB particularly the role of humoral immunity and IL‐17 in latent tuberculosis; related to the proinflammatory state and generation of a broad spectrum of reactions either toward Th1 responses favoring stimulation by cytokines or by antibodies and those toward diminished responses by Th2 cytokines or blocking by antibodies; possibly involving mechanisms of antibody dependent protection from Mtb by different subclasses of IgG. Of importance, the cross‐talk between Candida and Tuberculin mRNA responses need to be compared with signatures produced by other antigens(LPS and Streptococcus) to determine their importance and specificity in the pro‐inflammation state of individuals of different populations and their role in immune responses; vaccinations or infectious diseases.

Dr. Yunis is presently a Professor of pathology at The Brigham and Women’s Hospital, Harvard Medical School and Distinguished Physician in Medical Oncology at the department of Cancer Immunology and AIDS at Dana Farber Cancer Institute. He has received many awards, including the Rose Payne of the American Society of Histocompatibility and Immunogenetics in 1992, The Philip Levine of the American Association of Blood Banks, 1987, the Hispanic Scientist of the year at MOSI, Tampa, FL in 2005 among others. Moreover, Dr. Yunis has made numerous contributions in immunogenetics, immunobiology, genetic diversity, infections, autoimmune diseases, and aging.

GTC’s Antibody Design and Discovery Conference, leading industry and academic innovators from Pfizer, Merck, The Scripps Research Institute, MedImmune, NIH, Dana- Farber Cancer Institute, and more to discuss exciting clinical trends and applications of antibodies. We’ll explore novel technologies being utilized to identify and select antibodies with better accuracy and efficiency, and learn about new optimization and developability techniques to enhance effective function. Moreover, attendees will hear directly from scientists and researchers about emerging clinical data, and its implications for the advancement of the field, including therapeutic antibodies in cancer, and infectious and autoimmune diseases.

This conference is also part of the Drug Discovery and Regulatory Summit, which consists of this track and three other tracks:

- Biospecimens and Biorepositories
- 6th Drug Design and Medicinal Chemistry
- Life Science Legal and Business Strategy

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Edmond Yunis to Speak at Antibody Conference June 7-8 in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)